title: Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.
abstract: Many studies have been conducted concerning discontinuation of biologic disease-modifying anti-rheumatic drugs (DMARD), but mainly in trial settings which result in limited generalisability. Registry studies can complement the current literature of biologic DMARD discontinuation by providing more generalisable information. However, it may be necessary to combine registries to increase power and provide more diverse patient populations. This increased power could provide us information about risk and benefits of discontinuing biologic DMARD in typical clinical practice. However, use of multiple registries is not without challenges. In this review, we discuss the challenges to combining data across multiple registries, focusing on biologic discontinuation as an example. Challenges include: 1) generalizability of each registry; 2) new versus prevalent users designs; 3) outcome definitions; 4) different health care systems; 5) different follow up intervals; and 6) data harmonisation. The first three apply to each registry, and the last three apply to combining multiple registries. This review describes these challenges, corresponding solutions, and potential future opportunities.
authors.affiliation: Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. kazukiyoshida@mail.harvard.edu.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Yoshida
authors.forename: Helga
authors.initials: H
authors.lastname: Radner
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: Yoon-Kyoung
authors.initials: YK
authors.lastname: Sung
authors.forename: Sang-Cheol
authors.initials: SC
authors.lastname: Bae
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Kishimoto
authors.forename: Kazuo
authors.initials: K
authors.lastname: Matsui
authors.forename: Masato
authors.initials: M
authors.lastname: Okada
authors.forename: Shigeto
authors.initials: S
authors.lastname: Tohma
authors.forename: Michael E
authors.initials: ME
authors.lastname: Weinblatt
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Solomon
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000008:administration & dosage* / Q000009:adverse effects; D057225:Data Mining; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D012008:Recurrence; D012042:Registries; D012074:Remission Induction; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products